Clinical Trial Update: Gene Modified Allogeneic Neuroblastoma Cells For Treatment of Relapsed/Refractory Neuroblastoma [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating gene-modified allogeneic neuroblastoma cells for relapsed or refractory neuroblastoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroblastoma

Drugs mentioned

• Gene Modified Allogeneic Neuroblastoma Cells

Snippet

Sponsor: St. Jude Children's Research Hospital | Conditions: Neuroblastoma | Phase 1 | Status: COMPLETED